Seeking Alpha

A kidney cancer drug from Aveo Pharmaceuticals (AVEO) outperformed an approved drug from Onyx...

A kidney cancer drug from Aveo Pharmaceuticals (AVEO) outperformed an approved drug from Onyx Pharmaceuticals (ONXX) in a late-stage study comparing the two treatments head-to-head. Based on these data, the firm says it plans to submit for marketing approval of tivozanib in the United States and Europe this year.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|